Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

  1. Wei, Fang-Fei ORCID logo
  2. Pellicori, Pierpaolo ORCID logo
  3. Ferreira, João Pedro ORCID logo
  4. Gonzalez, Arantxa ORCID logo
  5. Mariottoni, Beatrice
  6. An, Dewei ORCID logo
  7. Verdonschot, Job ORCID logo
  8. Liu, Chen ORCID logo
  9. Ahmed, Fozia ORCID logo
  10. Petutschnigg, Johannes ORCID logo
  11. Rossignol, Patrick ORCID logo
  12. Heymans, Stephane ORCID logo
  13. Cuthbert, Joe
  14. Girerd, Nicolas ORCID logo
  15. Clark, Andrew ORCID logo
  16. Li, Yan ORCID logo
  17. Nawrot, Tim ORCID logo
  18. Muñiz-Sáenz-Diez, Javier ORCID logo
  19. Zannad, Faiez ORCID logo
  20. Cleland, John George Franklin ORCID logo
  21. Staessen, Jan A. ORCID logo
  22. on behalf of the HOMAGE Investigators
  23. Asayama, Kei
  24. Bozec, Erwan
  25. Brunner La Rocca, Hans P.
  26. Cosmi, Franco
  27. Cleland, John G. F.
  28. Collier, Tim
  29. Díez, Javier
  30. Edelmann, Frank
  31. Ferreira, João P.
  32. Girerd, Nicolas
  33. Grojean, Stephanie
  34. Hazebroek, Mark
  35. Heymans, Stephane
  36. Hansen, Tine W.
  37. Khan, Javed
  38. López, Begoñia
  39. Latini, Roberto
  40. Mariottoni, Beatrice
  41. McDonald, Ken
  42. Maestre, Gladys E.
  43. Moreno, María U.
  44. Mamas, Mamas A.
  45. Pizard, Anne
  46. Pieske, Burkert
  47. Petutschnigg, Johannes
  48. Pellicori, Pierpaolo
  49. Rossignol, Patrick
  50. Rouet, Philippe
  51. Ravassa, Suzanna
  52. Staessen, Jan A.
  53. Thijs, Lutgarde
  54. Verdonschot, Job A. J.
  55. Wei, Fang-Fei
  56. Zannad, Faiez

Download
41440_2024_Article_1843.pdf 2,46MB
WeightNameValue
1000 Titel
  • Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
1000 Autor/in
  1. Wei, Fang-Fei |
  2. Pellicori, Pierpaolo |
  3. Ferreira, João Pedro |
  4. Gonzalez, Arantxa |
  5. Mariottoni, Beatrice |
  6. An, Dewei |
  7. Verdonschot, Job |
  8. Liu, Chen |
  9. Ahmed, Fozia |
  10. Petutschnigg, Johannes |
  11. Rossignol, Patrick |
  12. Heymans, Stephane |
  13. Cuthbert, Joe |
  14. Girerd, Nicolas |
  15. Clark, Andrew |
  16. Li, Yan |
  17. Nawrot, Tim |
  18. Muñiz-Sáenz-Diez, Javier |
  19. Zannad, Faiez |
  20. Cleland, John George Franklin |
  21. Staessen, Jan A. |
  22. on behalf of the HOMAGE Investigators |
  23. Asayama, Kei |
  24. Bozec, Erwan |
  25. Brunner La Rocca, Hans P. |
  26. Cosmi, Franco |
  27. Cleland, John G. F. |
  28. Collier, Tim |
  29. Díez, Javier |
  30. Edelmann, Frank |
  31. Ferreira, João P. |
  32. Girerd, Nicolas |
  33. Grojean, Stephanie |
  34. Hazebroek, Mark |
  35. Heymans, Stephane |
  36. Hansen, Tine W. |
  37. Khan, Javed |
  38. López, Begoñia |
  39. Latini, Roberto |
  40. Mariottoni, Beatrice |
  41. McDonald, Ken |
  42. Maestre, Gladys E. |
  43. Moreno, María U. |
  44. Mamas, Mamas A. |
  45. Pizard, Anne |
  46. Pieske, Burkert |
  47. Petutschnigg, Johannes |
  48. Pellicori, Pierpaolo |
  49. Rossignol, Patrick |
  50. Rouet, Philippe |
  51. Ravassa, Suzanna |
  52. Staessen, Jan A. |
  53. Thijs, Lutgarde |
  54. Verdonschot, Job A. J. |
  55. Wei, Fang-Fei |
  56. Zannad, Faiez |
1000 Verlag Springer Nature Singapore
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-09-06
1000 Erschienen in
1000 Quellenangabe
  • 47(11):3225-3236
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41440-024-01843-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534698/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>None of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25–50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9. Quality of life (QoL) was assessed by EQ5D questionnaire. Between-group differences (spironolactone minus control [Δs]) were analyzed by repeated measures ANOVA with adjustment for baseline and, if appropriate, additionally for sex, age and body mass index. Δs in the pre-exercise systolic/diastolic BP were −8.00 mm Hg (95% CI, −11.6 to −4.43)/−0.85 mm Hg (−2.96 to 1.26) at month 1 and −9.58 mm Hg (−14.0 to −5.19)/−3.84 mm Hg (−6.22 to −1.47) at month 9. Δs in the post-exercise systolic/diastolic BP were −8.08 mm Hg (−14.2 to −2.01)/−2.07 mm Hg (−5.79 to 1.65) and −13.3 mm Hg (−19.9 to −6.75)/−4.62 mm Hg (−8.07 to −1.17), respectively. For completed shuttles, Δs at months 1 and 9 were 2.15 (−0.10 to 4.40) and 2.49 (−0.79 to 5.67), respectively. Δs in QoL were not significant. The correlations between the exercise-induced BP increases and the number of completed shuttles were similar in both groups. In conclusion, in patients at increased risk of developing HF, spironolactone reduced the pre- and post-exercise BP, but did not improve exercise capacity or QoL.</jats:p>
1000 Sacherschließung
lokal Female [MeSH]
lokal Heart failure
lokal Aged [MeSH]
lokal Heart Failure/drug therapy [MeSH]
lokal Heart Failure/physiopathology [MeSH]
lokal Humans [MeSH]
lokal Blood Pressure/drug effects [MeSH]
lokal Mineralocorticoid Receptor Antagonists/therapeutic use [MeSH]
lokal Treatment Outcome [MeSH]
lokal Middle Aged [MeSH]
lokal Diuretics/therapeutic use [MeSH]
lokal Incremental shuttle walk test
lokal Article
lokal Male [MeSH]
lokal Coronary heart disease
lokal Quality of Life [MeSH]
lokal Spironolactone
lokal Exercise capacity
lokal Spironolactone/therapeutic use [MeSH]
lokal article
lokal Exercise [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-4254-5215|https://orcid.org/0000-0001-7175-0464|https://orcid.org/0000-0002-2304-6138|https://orcid.org/0000-0001-5986-6528|https://frl.publisso.de/adhoc/uri/TWFyaW90dG9uaSwgQmVhdHJpY2U=|https://orcid.org/0000-0002-1395-7050|https://orcid.org/0000-0001-5549-1298|https://orcid.org/0000-0002-9818-0454|https://orcid.org/0000-0002-3678-1799|https://orcid.org/0000-0003-3116-9450|https://orcid.org/0000-0001-8009-3873|https://orcid.org/0000-0001-9477-7803|https://frl.publisso.de/adhoc/uri/Q3V0aGJlcnQsIEpvZQ==|https://orcid.org/0000-0002-3278-2057|https://orcid.org/0000-0001-8362-668X|https://orcid.org/0000-0002-5825-5968|https://orcid.org/0000-0002-3583-3593|https://orcid.org/0000-0003-0079-6996|https://orcid.org/0000-0001-7456-1570|https://orcid.org/0000-0002-1471-7016|https://orcid.org/0000-0002-3026-1637|https://frl.publisso.de/adhoc/uri/b24gYmVoYWxmIG9mIHRoZSBIT01BR0UgSW52ZXN0aWdhdG9ycw==|https://frl.publisso.de/adhoc/uri/QXNheWFtYSwgS2Vp|https://frl.publisso.de/adhoc/uri/Qm96ZWMsIEVyd2Fu|https://frl.publisso.de/adhoc/uri/QnJ1bm5lciBMYSBSb2NjYSwgSGFucyBQLg==|https://frl.publisso.de/adhoc/uri/Q29zbWksIEZyYW5jbw==|https://frl.publisso.de/adhoc/uri/Q2xlbGFuZCwgSm9obiBHLiBGLg==|https://frl.publisso.de/adhoc/uri/Q29sbGllciwgVGlt|https://frl.publisso.de/adhoc/uri/RMOtZXosIEphdmllcg==|https://frl.publisso.de/adhoc/uri/RWRlbG1hbm4sIEZyYW5r|https://frl.publisso.de/adhoc/uri/RmVycmVpcmEsIEpvw6NvIFAu|https://frl.publisso.de/adhoc/uri/R2lyZXJkLCBOaWNvbGFz|https://frl.publisso.de/adhoc/uri/R3JvamVhbiwgU3RlcGhhbmll|https://frl.publisso.de/adhoc/uri/SGF6ZWJyb2VrLCBNYXJr|https://frl.publisso.de/adhoc/uri/SGV5bWFucywgU3RlcGhhbmU=|https://frl.publisso.de/adhoc/uri/SGFuc2VuLCBUaW5lIFcu|https://frl.publisso.de/adhoc/uri/S2hhbiwgSmF2ZWQ=|https://frl.publisso.de/adhoc/uri/TMOzcGV6LCBCZWdvw7FpYQ==|https://frl.publisso.de/adhoc/uri/TGF0aW5pLCBSb2JlcnRv|https://frl.publisso.de/adhoc/uri/TWFyaW90dG9uaSwgQmVhdHJpY2U=|https://frl.publisso.de/adhoc/uri/TWNEb25hbGQsIEtlbg==|https://frl.publisso.de/adhoc/uri/TWFlc3RyZSwgR2xhZHlzIEUu|https://frl.publisso.de/adhoc/uri/TW9yZW5vLCBNYXLDrWEgVS4=|https://frl.publisso.de/adhoc/uri/TWFtYXMsIE1hbWFzIEEu|https://frl.publisso.de/adhoc/uri/UGl6YXJkLCBBbm5l|https://frl.publisso.de/adhoc/uri/UGllc2tlLCBCdXJrZXJ0|https://frl.publisso.de/adhoc/uri/UGV0dXRzY2huaWdnLCBKb2hhbm5lcw==|https://frl.publisso.de/adhoc/uri/UGVsbGljb3JpLCBQaWVycGFvbG8=|https://frl.publisso.de/adhoc/uri/Um9zc2lnbm9sLCBQYXRyaWNr|https://frl.publisso.de/adhoc/uri/Um91ZXQsIFBoaWxpcHBl|https://frl.publisso.de/adhoc/uri/UmF2YXNzYSwgU3V6YW5uYQ==|https://frl.publisso.de/adhoc/uri/U3RhZXNzZW4sIEphbiBBLg==|https://frl.publisso.de/adhoc/uri/VGhpanMsIEx1dGdhcmRl|https://frl.publisso.de/adhoc/uri/VmVyZG9uc2Nob3QsIEpvYiBBLiBKLg==|https://frl.publisso.de/adhoc/uri/V2VpLCBGYW5nLUZlaQ==|https://frl.publisso.de/adhoc/uri/WmFubmFkLCBGYWlleg==
1000 Hinweis
  • DeepGreen-ID: 3970a7e849814513bdf9abcb4e279840 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6491766.rdf
1000 Erstellt am 2025-02-03T15:33:23.760+0100
1000 Erstellt von 322
1000 beschreibt frl:6491766
1000 Zuletzt bearbeitet 2025-09-13T17:37:57.798+0200
1000 Objekt bearb. Sat Sep 13 17:37:57 CEST 2025
1000 Vgl. frl:6491766
1000 Oai Id
  1. oai:frl.publisso.de:frl:6491766 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source